Review



human m 7 g small-rna modification microarray  (Arraystar inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Arraystar inc human m 7 g small-rna modification microarray
    High expression of mtiRL involved in bladder cancer malignancy. A) tRNA modification was analyzed using LC/MS in multistage CdCl 2 malignant transformed cells. B) Small RNA sequencing in multistage CdCl 2 malignant transformed cells. C) Trend analysis of tRFs & tiRNAs. D) Model 41 in which the expression of tRFs & tiRNAs was increased upon the prolonging CdCl 2 treatment time. E) Analyzed expression of m 7 G‐tRF&tiRNA using Arraystar Human m 7 G small RNA modification <t>microarray</t> in METTL1‐knockout T24 cells and control cells. F) m 7 G motif tested in Arraystar Human m 7 G small RNA modification microarray. G) 12 tRFs&tiRNAs containing m 7 G motif were significantly up‐regulated, while 94 containing m 7 G motif significantly down‐regulated after METTL1‐knockout. H) A Venn analysis on tRFs&tiRNAs in trend analysis model 41 and downregulated tRFs&tiRNAs. I) The abundance of m 7 G −3′tiRNA Lys TTT ‐10 (mtiRL) were detected in SV‐HUC‐1, Cd‐SV‐HUC‐1 and T24 cells by m 7 G immunoprecipitation‐ Stem‐loop RT PCR method. J) The Sanger sequencing of the PCR products mtiRL. K) Northern blot further confirmed the expression of mtiRL in SV‐HUC‐1 and Cd‐SV‐HUC‐1 cells. L) The results indicated that mtiRL decreased significantly in knockout METTL1 T24 cells. M) The expression of mtiRL was tested in para‐tumor (n = 7), NMIBC(n = 7) and MIBC samples(n = 7). N) The level of mtiRL was measured in 10 bladder tumor tissues from Benzopyrene‐induced multiple organ mice carcinogenesis models. O) Multi‐stage models of carcinogenesis using CdCl 2 were constructed. P) Bladder cancer subtypes were determined by HE staining and the IHC expressions of Ki67and urothelial lineage markers CK5. Q) The expression of mtiRL in multi‐stage bladder tissues was tested. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Human M 7 G Small Rna Modification Microarray, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human m 7 g small-rna modification microarray/product/Arraystar inc
    Average 90 stars, based on 1 article reviews
    human m 7 g small-rna modification microarray - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "A Novel tsRNA, m 7 G‐3′ tiRNA Lys TTT , Promotes Bladder Cancer Malignancy Via Regulating ANXA2 Phosphorylation"

    Article Title: A Novel tsRNA, m 7 G‐3′ tiRNA Lys TTT , Promotes Bladder Cancer Malignancy Via Regulating ANXA2 Phosphorylation

    Journal: Advanced Science

    doi: 10.1002/advs.202400115

    High expression of mtiRL involved in bladder cancer malignancy. A) tRNA modification was analyzed using LC/MS in multistage CdCl 2 malignant transformed cells. B) Small RNA sequencing in multistage CdCl 2 malignant transformed cells. C) Trend analysis of tRFs & tiRNAs. D) Model 41 in which the expression of tRFs & tiRNAs was increased upon the prolonging CdCl 2 treatment time. E) Analyzed expression of m 7 G‐tRF&tiRNA using Arraystar Human m 7 G small RNA modification microarray in METTL1‐knockout T24 cells and control cells. F) m 7 G motif tested in Arraystar Human m 7 G small RNA modification microarray. G) 12 tRFs&tiRNAs containing m 7 G motif were significantly up‐regulated, while 94 containing m 7 G motif significantly down‐regulated after METTL1‐knockout. H) A Venn analysis on tRFs&tiRNAs in trend analysis model 41 and downregulated tRFs&tiRNAs. I) The abundance of m 7 G −3′tiRNA Lys TTT ‐10 (mtiRL) were detected in SV‐HUC‐1, Cd‐SV‐HUC‐1 and T24 cells by m 7 G immunoprecipitation‐ Stem‐loop RT PCR method. J) The Sanger sequencing of the PCR products mtiRL. K) Northern blot further confirmed the expression of mtiRL in SV‐HUC‐1 and Cd‐SV‐HUC‐1 cells. L) The results indicated that mtiRL decreased significantly in knockout METTL1 T24 cells. M) The expression of mtiRL was tested in para‐tumor (n = 7), NMIBC(n = 7) and MIBC samples(n = 7). N) The level of mtiRL was measured in 10 bladder tumor tissues from Benzopyrene‐induced multiple organ mice carcinogenesis models. O) Multi‐stage models of carcinogenesis using CdCl 2 were constructed. P) Bladder cancer subtypes were determined by HE staining and the IHC expressions of Ki67and urothelial lineage markers CK5. Q) The expression of mtiRL in multi‐stage bladder tissues was tested. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Figure Legend Snippet: High expression of mtiRL involved in bladder cancer malignancy. A) tRNA modification was analyzed using LC/MS in multistage CdCl 2 malignant transformed cells. B) Small RNA sequencing in multistage CdCl 2 malignant transformed cells. C) Trend analysis of tRFs & tiRNAs. D) Model 41 in which the expression of tRFs & tiRNAs was increased upon the prolonging CdCl 2 treatment time. E) Analyzed expression of m 7 G‐tRF&tiRNA using Arraystar Human m 7 G small RNA modification microarray in METTL1‐knockout T24 cells and control cells. F) m 7 G motif tested in Arraystar Human m 7 G small RNA modification microarray. G) 12 tRFs&tiRNAs containing m 7 G motif were significantly up‐regulated, while 94 containing m 7 G motif significantly down‐regulated after METTL1‐knockout. H) A Venn analysis on tRFs&tiRNAs in trend analysis model 41 and downregulated tRFs&tiRNAs. I) The abundance of m 7 G −3′tiRNA Lys TTT ‐10 (mtiRL) were detected in SV‐HUC‐1, Cd‐SV‐HUC‐1 and T24 cells by m 7 G immunoprecipitation‐ Stem‐loop RT PCR method. J) The Sanger sequencing of the PCR products mtiRL. K) Northern blot further confirmed the expression of mtiRL in SV‐HUC‐1 and Cd‐SV‐HUC‐1 cells. L) The results indicated that mtiRL decreased significantly in knockout METTL1 T24 cells. M) The expression of mtiRL was tested in para‐tumor (n = 7), NMIBC(n = 7) and MIBC samples(n = 7). N) The level of mtiRL was measured in 10 bladder tumor tissues from Benzopyrene‐induced multiple organ mice carcinogenesis models. O) Multi‐stage models of carcinogenesis using CdCl 2 were constructed. P) Bladder cancer subtypes were determined by HE staining and the IHC expressions of Ki67and urothelial lineage markers CK5. Q) The expression of mtiRL in multi‐stage bladder tissues was tested. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Techniques Used: Expressing, Modification, Liquid Chromatography with Mass Spectroscopy, Transformation Assay, RNA Sequencing, RNA modification, Microarray, Knock-Out, Control, Immunoprecipitation, Reverse Transcription Polymerase Chain Reaction, Sequencing, Northern Blot, Construct, Staining



    Similar Products

    human m 7 g small-rna modification microarray  (Arraystar inc)
    90
    Arraystar inc human m 7 g small-rna modification microarray
    High expression of mtiRL involved in bladder cancer malignancy. A) tRNA modification was analyzed using LC/MS in multistage CdCl 2 malignant transformed cells. B) Small RNA sequencing in multistage CdCl 2 malignant transformed cells. C) Trend analysis of tRFs & tiRNAs. D) Model 41 in which the expression of tRFs & tiRNAs was increased upon the prolonging CdCl 2 treatment time. E) Analyzed expression of m 7 G‐tRF&tiRNA using Arraystar Human m 7 G small RNA modification <t>microarray</t> in METTL1‐knockout T24 cells and control cells. F) m 7 G motif tested in Arraystar Human m 7 G small RNA modification microarray. G) 12 tRFs&tiRNAs containing m 7 G motif were significantly up‐regulated, while 94 containing m 7 G motif significantly down‐regulated after METTL1‐knockout. H) A Venn analysis on tRFs&tiRNAs in trend analysis model 41 and downregulated tRFs&tiRNAs. I) The abundance of m 7 G −3′tiRNA Lys TTT ‐10 (mtiRL) were detected in SV‐HUC‐1, Cd‐SV‐HUC‐1 and T24 cells by m 7 G immunoprecipitation‐ Stem‐loop RT PCR method. J) The Sanger sequencing of the PCR products mtiRL. K) Northern blot further confirmed the expression of mtiRL in SV‐HUC‐1 and Cd‐SV‐HUC‐1 cells. L) The results indicated that mtiRL decreased significantly in knockout METTL1 T24 cells. M) The expression of mtiRL was tested in para‐tumor (n = 7), NMIBC(n = 7) and MIBC samples(n = 7). N) The level of mtiRL was measured in 10 bladder tumor tissues from Benzopyrene‐induced multiple organ mice carcinogenesis models. O) Multi‐stage models of carcinogenesis using CdCl 2 were constructed. P) Bladder cancer subtypes were determined by HE staining and the IHC expressions of Ki67and urothelial lineage markers CK5. Q) The expression of mtiRL in multi‐stage bladder tissues was tested. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Human M 7 G Small Rna Modification Microarray, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human m 7 g small-rna modification microarray/product/Arraystar inc
    Average 90 stars, based on 1 article reviews
    human m 7 g small-rna modification microarray - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier
    human m 7 g small rna modification microarray  (Arraystar inc)
    90
    Arraystar inc human m 7 g small rna modification microarray
    High expression of mtiRL involved in bladder cancer malignancy. A) tRNA modification was analyzed using LC/MS in multistage CdCl 2 malignant transformed cells. B) Small RNA sequencing in multistage CdCl 2 malignant transformed cells. C) Trend analysis of tRFs & tiRNAs. D) Model 41 in which the expression of tRFs & tiRNAs was increased upon the prolonging CdCl 2 treatment time. E) Analyzed expression of m 7 G‐tRF&tiRNA using Arraystar Human m 7 G small RNA modification <t>microarray</t> in METTL1‐knockout T24 cells and control cells. F) m 7 G motif tested in Arraystar Human m 7 G small RNA modification microarray. G) 12 tRFs&tiRNAs containing m 7 G motif were significantly up‐regulated, while 94 containing m 7 G motif significantly down‐regulated after METTL1‐knockout. H) A Venn analysis on tRFs&tiRNAs in trend analysis model 41 and downregulated tRFs&tiRNAs. I) The abundance of m 7 G −3′tiRNA Lys TTT ‐10 (mtiRL) were detected in SV‐HUC‐1, Cd‐SV‐HUC‐1 and T24 cells by m 7 G immunoprecipitation‐ Stem‐loop RT PCR method. J) The Sanger sequencing of the PCR products mtiRL. K) Northern blot further confirmed the expression of mtiRL in SV‐HUC‐1 and Cd‐SV‐HUC‐1 cells. L) The results indicated that mtiRL decreased significantly in knockout METTL1 T24 cells. M) The expression of mtiRL was tested in para‐tumor (n = 7), NMIBC(n = 7) and MIBC samples(n = 7). N) The level of mtiRL was measured in 10 bladder tumor tissues from Benzopyrene‐induced multiple organ mice carcinogenesis models. O) Multi‐stage models of carcinogenesis using CdCl 2 were constructed. P) Bladder cancer subtypes were determined by HE staining and the IHC expressions of Ki67and urothelial lineage markers CK5. Q) The expression of mtiRL in multi‐stage bladder tissues was tested. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.
    Human M 7 G Small Rna Modification Microarray, supplied by Arraystar inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human m 7 g small rna modification microarray/product/Arraystar inc
    Average 90 stars, based on 1 article reviews
    human m 7 g small rna modification microarray - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    High expression of mtiRL involved in bladder cancer malignancy. A) tRNA modification was analyzed using LC/MS in multistage CdCl 2 malignant transformed cells. B) Small RNA sequencing in multistage CdCl 2 malignant transformed cells. C) Trend analysis of tRFs & tiRNAs. D) Model 41 in which the expression of tRFs & tiRNAs was increased upon the prolonging CdCl 2 treatment time. E) Analyzed expression of m 7 G‐tRF&tiRNA using Arraystar Human m 7 G small RNA modification microarray in METTL1‐knockout T24 cells and control cells. F) m 7 G motif tested in Arraystar Human m 7 G small RNA modification microarray. G) 12 tRFs&tiRNAs containing m 7 G motif were significantly up‐regulated, while 94 containing m 7 G motif significantly down‐regulated after METTL1‐knockout. H) A Venn analysis on tRFs&tiRNAs in trend analysis model 41 and downregulated tRFs&tiRNAs. I) The abundance of m 7 G −3′tiRNA Lys TTT ‐10 (mtiRL) were detected in SV‐HUC‐1, Cd‐SV‐HUC‐1 and T24 cells by m 7 G immunoprecipitation‐ Stem‐loop RT PCR method. J) The Sanger sequencing of the PCR products mtiRL. K) Northern blot further confirmed the expression of mtiRL in SV‐HUC‐1 and Cd‐SV‐HUC‐1 cells. L) The results indicated that mtiRL decreased significantly in knockout METTL1 T24 cells. M) The expression of mtiRL was tested in para‐tumor (n = 7), NMIBC(n = 7) and MIBC samples(n = 7). N) The level of mtiRL was measured in 10 bladder tumor tissues from Benzopyrene‐induced multiple organ mice carcinogenesis models. O) Multi‐stage models of carcinogenesis using CdCl 2 were constructed. P) Bladder cancer subtypes were determined by HE staining and the IHC expressions of Ki67and urothelial lineage markers CK5. Q) The expression of mtiRL in multi‐stage bladder tissues was tested. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Journal: Advanced Science

    Article Title: A Novel tsRNA, m 7 G‐3′ tiRNA Lys TTT , Promotes Bladder Cancer Malignancy Via Regulating ANXA2 Phosphorylation

    doi: 10.1002/advs.202400115

    Figure Lengend Snippet: High expression of mtiRL involved in bladder cancer malignancy. A) tRNA modification was analyzed using LC/MS in multistage CdCl 2 malignant transformed cells. B) Small RNA sequencing in multistage CdCl 2 malignant transformed cells. C) Trend analysis of tRFs & tiRNAs. D) Model 41 in which the expression of tRFs & tiRNAs was increased upon the prolonging CdCl 2 treatment time. E) Analyzed expression of m 7 G‐tRF&tiRNA using Arraystar Human m 7 G small RNA modification microarray in METTL1‐knockout T24 cells and control cells. F) m 7 G motif tested in Arraystar Human m 7 G small RNA modification microarray. G) 12 tRFs&tiRNAs containing m 7 G motif were significantly up‐regulated, while 94 containing m 7 G motif significantly down‐regulated after METTL1‐knockout. H) A Venn analysis on tRFs&tiRNAs in trend analysis model 41 and downregulated tRFs&tiRNAs. I) The abundance of m 7 G −3′tiRNA Lys TTT ‐10 (mtiRL) were detected in SV‐HUC‐1, Cd‐SV‐HUC‐1 and T24 cells by m 7 G immunoprecipitation‐ Stem‐loop RT PCR method. J) The Sanger sequencing of the PCR products mtiRL. K) Northern blot further confirmed the expression of mtiRL in SV‐HUC‐1 and Cd‐SV‐HUC‐1 cells. L) The results indicated that mtiRL decreased significantly in knockout METTL1 T24 cells. M) The expression of mtiRL was tested in para‐tumor (n = 7), NMIBC(n = 7) and MIBC samples(n = 7). N) The level of mtiRL was measured in 10 bladder tumor tissues from Benzopyrene‐induced multiple organ mice carcinogenesis models. O) Multi‐stage models of carcinogenesis using CdCl 2 were constructed. P) Bladder cancer subtypes were determined by HE staining and the IHC expressions of Ki67and urothelial lineage markers CK5. Q) The expression of mtiRL in multi‐stage bladder tissues was tested. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.

    Article Snippet: We further analyzed the expression of m 7 G‐tRF and tiRNA using an Arraystar Human m 7 G small‐RNA modification microarray using METTL1‐knockout T24 cells and control cells.

    Techniques: Expressing, Modification, Liquid Chromatography with Mass Spectroscopy, Transformation Assay, RNA Sequencing, RNA modification, Microarray, Knock-Out, Control, Immunoprecipitation, Reverse Transcription Polymerase Chain Reaction, Sequencing, Northern Blot, Construct, Staining